Filing Details
- Accession Number:
- 0000899243-18-010157
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-04-13 19:02:34
- Reporting Period:
- 2018-04-06
- Accepted Time:
- 2018-04-13 19:02:34
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1103021 | Biodelivery Sciences International Inc | BDSI | Pharmaceutical Preparations (2834) | 352089858 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1301715 | A Mark Sirgo | C/O Biodelivery Sciences Intl, Inc., 4131 Parklake Avenue, Suite 225 Raleigh NC 27612 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-04-06 | 285,305 | $0.00 | 2,585,966 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2018-04-06 | 13,576 | $0.00 | 2,599,542 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2018-04-10 | 100,000 | $2.06 | 2,499,542 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | A | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2018-04-06 | 285,305 | $0.00 | 285,305 | $0.00 |
| Common Stock | Restricted Stock Units | Disposition | 2018-04-06 | 13,576 | $0.00 | 13,576 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2018-04-06 | No | 4 | A | Direct | |
| 0 | 2018-04-06 | No | 4 | A | Direct |
Footnotes
- Pursuant to the Reporting Person's retirement agreement previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission ("SEC") on August 29, 2017 (the "Retirement Agreement"), the future vesting of these Restricted Stock Units ("RSUs") terminated and in lieu the Reporting Person received a one-time issuance of the Issuer's common stock ("Common Stock"). Pursuant to a deferral, the vesting of these shares occurred on April 6, 2018.
- The shares of Common Stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. Pursuant to a deferral, the vesting of these shares occurred on April 6, 2018.
- On April 10, 2018, the Reporting Person sold an aggregate of 100,000 shares of the Common Stock at a weighted average price of $2.06 per share. The highest sale price for the Common Stock was $2.13 per share and the lowest sale price was $2.00 per share.
- The shares of Common Stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs.
- The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth in these footnotes.
Billionaire Hedge Funds
